Serum miR‑300 as a diagnostic and prognostic biomarker in osteosarcoma

Liu,Jian‑Dong; Xin,Qun; Tao,Chun‑Sheng; Sun,Pei‑Feng; Xu,Peng; Wu,Bing; Qu,Liang; Li,Shu-Zhong

doi:10.3892/ol.2016.5214

Serum miR‑300 as a diagnostic and prognostic biomarker in osteosarcoma

Authors:
- Jian‑Dong Liu
- Qun Xin
- Chun‑Sheng Tao
- Pei‑Feng Sun
- Peng Xu
- Bing Wu
- Liang Qu
- Shu-Zhong Li
View Affiliations

Affiliations: Department of Orthopedics, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of General Surgery, 401 Hospital of PLA, Qingdao, Shandong 266071, P.R. China, Department of Orthopedics, 401 Hospital of PLA, Qingdao, Shandong 266071, P.R. China
Published online on: September 29, 2016 https://doi.org/10.3892/ol.2016.5214
Pages: 3912-3918
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to determine whether microRNA (miR)‑300 is a diagnostic and prognostic biomarker in osteosarcoma, the miR‑300 levels in serum of 114 osteosarcoma patients and 114 healthy controls were compared, followed by serum analysis of the differences between the pre‑operative and post‑operative sera of these osteosarcoma patients. It was observed that the concentration levels of miR‑300 in the serum of osteosarcoma patients was significantly higher than those in the serum of healthy controls (P<0.01). Furthermore, the concentration levels of miR‑300 in the post‑operative serum were significantly reduced when compared with the pre‑operative serum levels (P<0.001). High miR‑300 levels in serum correlated significantly with clinical stage, distant metastasis and poor survival of osteosarcoma patients. Notably, serum miR‑300 was an independent prognostic marker for osteosarcoma. In conclusion, our results suggested that serum miR‑300 may be a potential and useful noninvasive biomarker for the early detection of osteosarcoma.

View Figures

View References

1	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
2	Teicher BA: Searching for molecular targets in sarcoma. Biochem Pharmacol. 84:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 21:2011–2018. 2003. View Article : Google Scholar : PubMed/NCBI
5	Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: Recent experience at the Rizzoli institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134. 2003. View Article : Google Scholar : PubMed/NCBI
6	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
7	Gorlick R: Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 152:467–478. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bruland ØS, Bauer H, Alvegaard T and Smeland S: Treatment of osteosarcoma. The Scandinavian sarcoma group experience. Cancer Treat Res. 152:309–318. 2009. View Article : Google Scholar : PubMed/NCBI
9	Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Ying HC, Xu HY, Lv J, Ying TS and Yang Q: MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol. 36:16–20. 2015.PubMed/NCBI
12	Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ziyan W, Shuhua Y, Xiufang W and Xiaoyun L: MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol. 28:1469–1474. 2011. View Article : Google Scholar : PubMed/NCBI
14	Bi Y, Jing Y and Cao Y: Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3. Tumour Biol. 36:8405–8411. 2015. View Article : Google Scholar : PubMed/NCBI
15	Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y, Yin G and Wen J: MicroRNA-204 inhibits proliferation, migration, invasion, and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1. Oncol Rep. 34:399–406. 2015.PubMed/NCBI
16	Wang W, Zhou X and Wei M: MicroRNA-144 suppresses osteosarcoma growth and metastasis by targeting ROCK1 and ROCK2. Oncotarget. 6:10297–10308. 2015. View Article : Google Scholar : PubMed/NCBI
17	Han K, Chen X, Bian N, Ma B, Yang T, Cai C, Fan Q, Zhou Y and Zhao TB: MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1. Oncotarget. 6:8875–8889. 2015. View Article : Google Scholar : PubMed/NCBI
18	Du JY, Wang LF, Wang Q and Yu LD: miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells. Oncol Rep. 33:1890–1898. 2015.PubMed/NCBI
19	Mao JH, Zhou RP, Peng AF, Liu ZL, Huang SH, Long XH and Shu Y: microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. Oncol Lett. 4:1125–1129. 2012.PubMed/NCBI
20	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
23	Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut. 58:1375–1381. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, Jing Q, Qin Y and Li Z: Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 56:602–609. 2011. View Article : Google Scholar : PubMed/NCBI
26	Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, et al: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 102:1174–1179. 2010. View Article : Google Scholar : PubMed/NCBI
27	Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 11:426–437. 2011. View Article : Google Scholar : PubMed/NCBI
28	Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010. View Article : Google Scholar : PubMed/NCBI
29	Cai H, Zhao H, Tang J and Wu H: Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. J Surg Res. 194:505–510. 2015. View Article : Google Scholar : PubMed/NCBI
30	Zhang C, Yao C, Li H, Wang G and He X: Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma. Int J Clin Exp Pathol. 7:4194–4203. 2014.PubMed/NCBI
31	Yuan J, Chen L, Chen X, Sun W and Zhou X: Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 40:2090–2097. 2012. View Article : Google Scholar : PubMed/NCBI
32	Xue Z, Zhao J, Niu L, An G, Guo Y and Ni L: Up-regulation of miR-300 promotes proliferation and invasion of osteosarcoma by targeting BRD7. PloS One. 10:e01276822015. View Article : Google Scholar : PubMed/NCBI
33	Yu J, Xie F, Bao X, Chen W and Xu Q: miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting twist in human epithelial cancer. Mol Cancer. 13:1212014. View Article : Google Scholar : PubMed/NCBI
34	Zhang D, Yang G, Chen X, Li C, Wang L, Liu Y, Han D, Liu H, Hou X, Zhang W, et al: mir-300 promotes self-renewal and inhibits the differentiation of glioma stem-like cells. J Mol Neurosci. 53:637–644. 2014. View Article : Google Scholar : PubMed/NCBI
35	Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N, Zhang Y, Yang B and Wang Z: MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem. 282:12363–12367. 2007. View Article : Google Scholar : PubMed/NCBI
36	Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 105:849–859. 2013. View Article : Google Scholar : PubMed/NCBI